HUMANITAS MIRASOLE SPA

High Blood Eosinophils and FeNO Levels Predict Better Dupilumab Response in Moderate-to-Severe Asthma

• Post-hoc analysis of LIBERTY ASTHMA QUEST trial reveals patients with elevated blood eosinophils and FeNO levels show significantly higher odds of achieving clinical remission with dupilumab treatment. • Clinical remission, defined by four criteria including no exacerbations, no symptoms, no oral corticosteroids, and stable lung function, was achieved in 38.3% of dupilumab-treated patients versus 26.2% in placebo group. • Patients with blood eosinophil counts ≥150 cells/µL and FeNO levels ≥20 ppb showed the strongest response to dupilumab, with adjusted odds ratio of 2.63 for achieving clinical remission.